SCONE Study Studies on Complement regulation in atypical hemolytic uremic syndrome following hemodialysis, plasmapheresis and treatment with Eculizumab

SCONE Study Studies on Complement regulation in atypical hemolytic uremic syndrome following hemodialysis, plasmapheresis and treatment with Eculizumab - SCONE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37013

Enrollment

Registered

2012-10-09

Start date

2012-12-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemolytic uremic syndrome HUS

Interventions

None listed

Eligibility

Age

12 Years to 99 Years

Inclusion criteria

Inclusion criteria: - age more than 12 years - diagnosis of atypical HUS - treatment either with hemodialysis, plasmapheresis or eculizumab - after giving written informed consent

Exclusion criteria

Exclusion criteria: no informed consent

Design outcomes

Primary

Measure	Time frame
Tests: -Levels of complement factors: C3, C3b, Complement Factor H quantitative (ELISA), Complement factor I (ELISA), CFB, sC5-9 membrane attack complex, Presence of C3b on erythrocytes, Functional assay: Complement Factor H, MCP expression on leucocytes (flow cytometer), tests of coagulation and endothelial function, Micro endothelial particles, circulating DNA (nucleosomen), FSAP (factor VII-activating protease.	—

Measure

Time frame

Tests: -Levels of complement factors: C3, C3b, Complement Factor H quantitative (ELISA), Complement factor I (ELISA), CFB, sC5-9 membrane attack complex, Presence of C3b on erythrocytes, Functional assay: Complement Factor H, MCP expression on leucocytes (flow cytometer), tests of coagulation and endothelial function, Micro endothelial particles, circulating DNA (nucleosomen), FSAP (factor VII-activating protease.

—

Countries

Netherlands

Outcome results